The global Implantable Infusion Pump Market is expected to reach a valuation of USD 485.1 Million in 2022.
The increasing incidence of numerous disorders such as diabetes, cancer, and various other disorders among the population, combined with the growing liability of the elderly population, advanced technology are projected to be the market's primary growth drivers.
Overall sales of implantable infusion pumps are projected to grow at a robust CAGR of 5.7% between 2022 and 2032, totaling around USD 892.6 Million by the end of 2032.
An implantable infusion pump is a medical device that administers drugs to patients via intra-arterial, intravenous, subcutaneous, intraperitoneal, intrathecal, and epidural routes. A catheter is strung into the chosen place after the pump is surgically implanted in a subcutaneous pocket in the abdominal wall.
An implantable infusion pump's primary function is to deliver fluids, such as supplements and drugs, into a patient's body in a controllable environment. Implantable infusion pump are frequently used in clinical settings such as hospitals, specialty clinics, ambulatory surgical centers, and so on.
| Data Points | Key Statistics |
|---|---|
| Implantable Infusion Pump Market Size (2022) | USD 485.1 Million |
| Implantable Infusion Pump Market Revenue Forecast (2032) | USD 892.6 Million |
| Implantable Infusion Pump Market Growth Rate (2022 to 2032) | 5.7% CAGR |
| North America Market Share | 36.7% |
The dosage is customized for each patient. The implantable infusion pump only require recharging every 1 to 3 months.
When employed to deliver drugs with FDA approval for this course of obtaining to and for the associated sign for the treatment of cancer, primary liver cancer, primary epithelial ovarian cancer, metastatic colorectal cancer, severe/chronic/intractable pain, and serious spasticity of cerebral origin in patients who are unresponsive to stand for oral baclofen therapeutic interventions, these medical devices are evaluated therapeutically crucial.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The principal factors propelling the expansion of the implantable infusion pump market are rising rates of cancer, diabetes, and obesity worldwide. A significant increase in implantable drug delivery techniques via surgeries is also driving up the consumption of infusion pump.
The delivery of chemotherapy agents and analgesics are the foremost activities; numerous implantable infusion pump are industrially obtainable to end users, which will drive sales at a significant rate over the forecasting period. The innovative implantable infusion pump provide long-term drug infusion at a differential or constant rate.
Contribution to progress from top manufacturers as a result of various factors, for example, growing prevalence of chronic diseases alongside an aging population, broadening adoption of convenient & advanced implantable infusion pump to reduce hospital facility use, and enduring increase in surgical procedural volumes.
Aside from that, advancements in technology and increased spending by manufacturers for the production of better implantable infusion pump will drive the development of this market, notably in the United States and Western Europe.
However, the FDA's stringent approval regulations for implantable infusion pump will constrain the industry's growth.
Furthermore, patient care risks and medical errors while drug delivery affiliated with implantable infusion pump in desirable areas may act as a limitation to the market's expansion. Product recalls and stringent regulations for innovative products may also restrict the overall implantable infusion pump market's growth throughout the forecast period.
North America is predicted to dominate the global Implantable Infusion Pump market in the coming years and account for a share of 36.7% of the global market in 2022. This dominance is due to the increasing number of chronic diseases, the purpose of healthcare infrastructure, and the presence of significant market players in the region.
Furthermore, supportive reimbursement programs covering the costs of implantable medical devices as well as the protocol inspired individuals in the region to choose such devices. Furthermore, the surging prevalence of chronic pain in the United States is anticipated to boost the market for implantable infusion pump.
According to CDC 2020 data, 20.4% of adults had chronic pain in 2019 and 7.4% of adults had severe pain that frequently restricted life or work activities. Both increased with age and were greatest among adults 65 and older.
As a result, soaring chronic pain cases are expected to increase demand for implantable infusion pump, which are surgically implanted to provide consistent drug delivery for pain management in non-cancer patients.
Furthermore, recent product authorization by the US Food and Drug Administration is anticipated to expand the regional market for implantable infusion pump.
The Asia Pacific, excluding Japan, is also predicted to experience substantial growth in the Implantable Infusion Pump Market owing to increased R&D activities, saturation in the advanced economies, and the advancement of healthcare infrastructure in this region.
The Asia-Pacific region, excluding Japan, has several small players that conduct business on a regional level and contribute to a significant portion of the Implantable Infusion Pump Market industry.
Improved medical infrastructure and steadily increasing disposable income in emerging economies such as China and India, among many others, are also cruising the implantable infusion pump market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The market for implantable infusion pump in Europe is predicted to expand at a 6.2% annual rate from 2022 to 2032. The global increase in the healthcare sector is accelerating the development of the Europe infusion pump market. Europe is accounting for a share of 29.5% of the global market in 2022.
One of the key factors driving the expansion of the implantable infusion pump market is the emergence of the prevalence of chronic illnesses throughout the region. Clamor for ambulatory implantable infusion pump in home health care settings, as well as a boost in the number of ICU beds in countries with a high prevalence of COVID-19, compel market growth.
Cancer (Oncology) is anticipated to represent the largest portion of the implantable infusion pump application segment. This is due to the rise in cases of cancer among the global population.
Cancer was the second-leading cause of death globally in 2018, causing an estimated 9.6 million deaths, or one in every six deaths, according to the WHO 2021 data, and approximately 300,000 new cases of cancer are detected each year among children aged 0-19 years.
Furthermore, 9,503,710 new cancer cases were reported in Asia, according to data from the Global Cancer Observatory 2020. As a result, rising cancer cases around the world may augment growth in the oncology segment.
Manufacturers are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential buyers and create a larger customer base. For instance,
Some leading implantable infusion pump manufacturers include B. Braun Melsungen AG., CareFusion Corporation, Fresenius Kabi AG, Terumo Corporation, Medtronic Plc., Baxter International Inc., Smiths Medical, MOOG Inc., Johnson & Johnson Private Ltd., and Hospira, Inc., Flowonix, The Tandem Diabetes Care.
These key implantable infusion pump providers are adopting various strategies such as new product launches and approvals, partnerships, collaborations, acquisitions, mergers, etc. to increase their sales and gain a competitive edge in the global implantable infusion pump market. For instance,
The global implantable infusion pump market reached USD 485.1 Million in 2022
As per FMI, the implantable infusion pump market is expected to grow at a CAGR of 5.7% from 2022-2032
The global sales of implantable infusion pumps are anticipated to total a valuation of USD 892.6 Million by 2032
North America will continue to remain the most lucrative, accounting for a share of 36.7% in 2022
| Estimated Size, 2025 | USD 308.2 million |
|---|---|
| Projected Size, 2035 | USD 763.9 million |
| Value-based CAGR (2025 to 2035) | 9.5% |
| Estimated Size, 2024 | USD 4,932.2 million |
|---|---|
| Projected Size, 2034 | USD 8,345.4 million |
| Value-based CAGR (2024 to 2034) | 5.2% |
| Market Value (2022) | USD 5059.7 million |
|---|---|
| Market Anticipated Forecast Value (2032) | USD 8509 million |
| Projected CAGR (2022 to 2032) | 4.8% |
Explore Therapeutic Device Insights
View Reports
Implantable Infusion Pump Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
